Tonstad S, Ose L, Gørbitz C, Harrison E M, de Koning Gans H J
Department of Medicine A, Rikshospitalet, Oslo, Norway.
Scand J Clin Lab Invest. 1993 Aug;53(5):457-63. doi: 10.1080/00365519309092540.
The effect of the combination of low-dose lovastatin and low-dose colestipol was studied among 57 subjects with moderate to severe primary hypercholesterolaemia (total cholesterol > or = 7.0 mmol l-1). Following an 8-week dietary phase, participants were randomized to treatment with 20 mg of lovastatin combined with 5 g or with 10 g of colestipol, or to matching placebo. Baseline total cholesterol was 7.7 +/- 0.9 mmol l-1 after dietary stabilization. Total cholesterol levels were reduced to 5.6 +/- 0.7 mmol l-1 and 5.8 +/- 0.7 mmol l-1 after 4 and 8 weeks of treatment in the lovastatin 5 g-1 colestipol group, and 74% of the subjects achieved the goal of low density lipoprotein (LDL) cholesterol levels of > or = 4.0 mmol l-1. Among the lovastatin 10 g-1 colestipol group, total cholesterol was reduced to 5.4 +/- 0.5 mmol l-1 and 5.5 +/- 0.9 mmol l-1 following 4 and 8 weeks, and 80% of subjects achieved the LDL cholesterol goal. No change was seen in the placebo group. Thus, low-dose combination therapy with lovastatin and colestipol, in conjunction with dietary treatment, is effective in moderate to severe primary hypercholesterolaemia, and is well tolerated.
在57例中度至重度原发性高胆固醇血症（总胆固醇≥7.0 mmol/L）患者中研究了低剂量洛伐他汀与低剂量考来烯胺联合用药的效果。经过8周的饮食阶段后，参与者被随机分配接受20 mg洛伐他汀与5 g或10 g考来烯胺联合治疗，或接受匹配的安慰剂治疗。饮食稳定后基线总胆固醇为7.7±0.9 mmol/L。在洛伐他汀5 g-考来烯胺组治疗4周和8周后，总胆固醇水平分别降至5.6±0.7 mmol/L和5.8±0.7 mmol/L，74%的受试者达到了低密度脂蛋白（LDL）胆固醇水平≥4.0 mmol/L的目标。在洛伐他汀10 g-考来烯胺组中，4周和8周后总胆固醇分别降至5.4±0.5 mmol/L和5.5±0.9 mmol/L，80%的受试者达到了LDL胆固醇目标。安慰剂组未见变化。因此，低剂量洛伐他汀与考来烯胺联合治疗，结合饮食治疗，对中度至重度原发性高胆固醇血症有效，且耐受性良好。
